newsLilly announces agreement to acquire Dermira for $1.1bn24 February 2020 | By Rachael Harper (European Pharmaceutical Review)Eli Lilly has announced it is to acquire Dermira for $18.75 per share, or approximately $1.1 billion, which will expand Lilly's immunology pipeline.